TY - JOUR
T1 - Patient recommendations for reducing long-lasting economic burden after breast cancer
AU - Dean, Lorraine T.
AU - Moss, Shadiya L.
AU - Rollinson, Sarah I.
AU - Frasso Jaramillo, Livia
AU - Paxton, Raheem J.
AU - Owczarzak, Jill T.
N1 - Funding Information:
This work was supported by the National Cancer Institute (grant K01CA184288 to Lorraine T. Dean), the National Institute of Mental Health (R25MH083620 to Lorraine T. Dean), the Johns Hopkins University Center for AIDS Research (grant P30AI094189 to Lorraine T. Dean, Sarah I. Rollinson, and Livia Frasso Jaramillo), the Sidney Kimmel Cancer Center (grant P30CA006973 to Lorraine T. Dean, Sarah I. Rollinson, and Livia Frasso Jaramillo), and the National Institute on Drug Abuse (grant T32DA031099 to Shadiya L. Moss).
Publisher Copyright:
© 2019 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Background: In the United States, patients who have breast cancer experience significant economic burden compared with those who have other types of cancers. Cancer-related economic burden is exacerbated by adverse treatment effects. Strategies to resolve the economic burden caused by breast cancer and its adverse treatment effects have stemmed from the perspectives of health care providers, oncology navigators, and other subject-matter experts. For the current study, patient-driven recommendations were elicited to reduce economic burden after 1) breast cancer and 2) breast cancer-related lymphedema, which is a common, persistent adverse effect of breast cancer. Methods: Qualitative interviews were conducted with 40 long-term breast cancer survivors who were residents of Pennsylvania or New Jersey in 2015 and were enrolled in a 6-month observational study. Purposive sampling ensured equal representation by age, socioeconomic position, and lymphedema diagnosis. Semistructured interviews addressed economic challenges, supports used, and patient recommendations for reducing financial challenges. Interviews were coded, and representative quotes from the patient recommendations were analyzed and reported to illustrate key findings. Results: Of 40 interviewees (mean age, 64 years; mean time since diagnosis, 12 years), 27 offered recommendations to reduce the economic burden caused by cancer and its adverse treatment effects. Nine recommendations emerged across 4 major themes: expanding affordable insurance and insurance-covered items, especially for lymphedema treatment (among the 60% who reported lymphedema); supportive domestic help; financial assistance from diagnosis through treatment; and employment-preserving policies. Conclusions: The current study yielded 9 actionable, patient-driven recommendations—changes to insurance, supportive services, financial assistance, and protective policies—to reduce breast cancer-related economic burden. These recommendations should be tested through policy and programmatic interventions.
AB - Background: In the United States, patients who have breast cancer experience significant economic burden compared with those who have other types of cancers. Cancer-related economic burden is exacerbated by adverse treatment effects. Strategies to resolve the economic burden caused by breast cancer and its adverse treatment effects have stemmed from the perspectives of health care providers, oncology navigators, and other subject-matter experts. For the current study, patient-driven recommendations were elicited to reduce economic burden after 1) breast cancer and 2) breast cancer-related lymphedema, which is a common, persistent adverse effect of breast cancer. Methods: Qualitative interviews were conducted with 40 long-term breast cancer survivors who were residents of Pennsylvania or New Jersey in 2015 and were enrolled in a 6-month observational study. Purposive sampling ensured equal representation by age, socioeconomic position, and lymphedema diagnosis. Semistructured interviews addressed economic challenges, supports used, and patient recommendations for reducing financial challenges. Interviews were coded, and representative quotes from the patient recommendations were analyzed and reported to illustrate key findings. Results: Of 40 interviewees (mean age, 64 years; mean time since diagnosis, 12 years), 27 offered recommendations to reduce the economic burden caused by cancer and its adverse treatment effects. Nine recommendations emerged across 4 major themes: expanding affordable insurance and insurance-covered items, especially for lymphedema treatment (among the 60% who reported lymphedema); supportive domestic help; financial assistance from diagnosis through treatment; and employment-preserving policies. Conclusions: The current study yielded 9 actionable, patient-driven recommendations—changes to insurance, supportive services, financial assistance, and protective policies—to reduce breast cancer-related economic burden. These recommendations should be tested through policy and programmatic interventions.
KW - United States
KW - breast cancer
KW - economic burden
KW - lymphedema
KW - qualitative analysis
UR - http://www.scopus.com/inward/record.url?scp=85062496779&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062496779&partnerID=8YFLogxK
U2 - 10.1002/cncr.32012
DO - 10.1002/cncr.32012
M3 - Article
C2 - 30839106
AN - SCOPUS:85062496779
VL - 125
SP - 1929
EP - 1940
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 11
ER -